Shire PLC (LON:SHP)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research note issued on Monday.

SHP has been the subject of several other research reports. Jefferies Group lifted their price target on shares of Shire PLC from GBX 6,050 ($74.88) to GBX 6,600 ($81.68) and gave the stock a “buy” rating in a research report on Wednesday, August 3rd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a research report on Friday, July 22nd. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Deutsche Bank AG reiterated a “buy” rating and set a GBX 6,200 ($76.73) price target on shares of Shire PLC in a research report on Wednesday, October 12th. Finally, Credit Suisse Group AG boosted their price objective on shares of Shire PLC from GBX 5,000 ($61.88) to GBX 5,200 ($64.36) and gave the company an “outperform” rating in a report on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of GBX 5,841.33 ($72.29).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 5118.00 on Monday. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00. The stock’s market cap is GBX 34.95 billion. The firm has a 50-day moving average of GBX 5,005.03 and a 200-day moving average of GBX 4,600.81.

The company also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were issued a dividend of GBX 3.51 ($0.04) per share. The ex-dividend date was Thursday, September 8th. This represents a yield of 0.07%.

In other news, insider Dominic Blakemore bought 133 shares of the stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average cost of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.